Role of α-Adrenergic Receptors in the Effect of the β-Adrenergic Receptor Ligands, CGP 12177, Bupranolol, and SR 59230A, on the Contraction of Rat Intrapulmonary Artery
Open Access
- 1 April 2004
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 309 (1) , 137-145
- https://doi.org/10.1124/jpet.103.061192
Abstract
This study investigates the effect of the aryloxypropanolamines 4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimidazol-2-one (CGP 12177), bupranolol, and 3-(2-ethylphenoxy)-1[(1S)-1,2,3,4-tetrahydronaphth-1-ylamino]-(2S)-2-propanol oxalate (SR 59230A) [commonly used as β3- and/or atypical β-adrenergic receptors (β-AR) ligands] on the contractile function of rat intralobar pulmonary artery. Affinities of β-AR ligands for α1-adrenergic receptors (α1-AR) were also evaluated using [3H]prazosin binding competition experiments performed in rat cortical membranes. In intralobar pulmonary artery, CGP 12177 did not modify the basal tone, but antagonized the contraction induced by the α1-AR agonist phenylephrine (PHE). In arteries precontracted with PHE, CGP 12177 elicited relaxation, whereas in those precontracted with prostaglandin F2α (PGF2α), it further enhanced contraction. CGP 12177 induced an increase in intracellular calcium concentration in pressurized arteries loaded with Fura PE-3 and precontracted with PGF2α. In PGF2α precontracted arteries, phentolamine (an α-AR antagonist) and phenoxybenzamine (an irreversible α-AR antagonist) antagonized the contractile responses to PHE and CGP 12177. Both responses were also decreased by bupranolol and SR 59230A. Specific [3H]prazosin binding was displaced by CGP 12177, bupranolol, and SR 59230A with pKi values of 5.2, 5.7, and 6.6, respectively. In contrast, (±)-(R*,R*)-[4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy]acetic acid sodium (BRL 37344) and disodium 5-[(2R)-2-([(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino)propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL 316243) (nonaryloxypropanolamines β3-AR agonists) displayed very low affinity for [3H]prazosin binding sites (pKi values below 4). These data suggest that CGP 12177 exhibits partial agonist properties for α1-AR in rat pulmonary artery. They also show that bupranolol and SR 59230A exert an α1-AR antagonist effect. As a consequence, these aryloxypropanolamine compounds should be used with caution when investigating the role of β3- and atypical β-AR in the regulation of vascular tone.Keywords
This publication has 43 references indexed in Scilit:
- Enhancement of α 2 -adrenoceptor-mediated vasoconstriction by the thromboxane-mimetic U46619 in the porcine isolated ear artery: role of the ERK-MAP kinase signal transduction cascadeBritish Journal of Pharmacology, 2003
- Evidence against β3 -adrenoceptors or low affinity state of β1 -adrenoceptors mediating relaxation in rat isolated aortaBritish Journal of Pharmacology, 2003
- RhoA/Rho kinase and nitric oxide modulate the agonist-induced pulmonary artery diameter response timeAmerican Journal of Physiology-Heart and Circulatory Physiology, 2002
- The putative β4-adrenergic receptor is a novel state of the β1-adrenergic receptorAmerican Journal of Physiology-Endocrinology and Metabolism, 2001
- β1‐, β2‐ and atypical β‐adrenoceptor‐mediated relaxation in rat isolated aortaBritish Journal of Pharmacology, 2000
- Influence of β-adrenoceptor agonists on the pulmonary circulation. Effects of a β3-adrenoceptor antagonist, SR 59230AEuropean Journal of Pharmacology, 1998
- Neuropeptide Y-induced potentiation of noradrenergic vasoconstriction in the human saphenous vein: involvement of endothelium generated thromboxaneBritish Journal of Pharmacology, 1998
- Presence of vasoconstrictor 5HT1-like receptors revealed by precontraction of rabbit isolated mesenteric arteryBritish Journal of Pharmacology, 1995
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973